Exposure to TARC alters beta2-adrenergic receptor signaling in human peripheral blood T lymphocytes

Irene H Heijink1, Edo Vellenga, Jaap Oostendorp

  • 1Department of Allergology, University Medical Center Groningen, The Netherlands.

Insights

Thymus and activation-regulated chemokine (TARC) impairs beta(2)-adrenergic receptor (beta(2)-AR) function in T cells. This involves Src kinase activation, leading to altered signaling pathways and potentially promoting T cell inflammation in asthma.

Area of Science:

  • Immunology
  • Cellular Signaling
  • Pharmacology

Background:

  • The beta(2)-adrenergic receptor (beta(2)-AR) regulates T cell activity via the cAMP pathway.
  • beta(2)-AR desensitization, through phosphorylation, impacts T cell function in asthma.

Purpose of the Study:

  • To investigate how TARC affects beta(2)-AR function and signaling in human T cells.
  • To elucidate the molecular mechanisms underlying TARC-mediated impairment of beta(2)-AR signaling.

Main Methods:

  • Isolated human T cells were treated with TARC and fenoterol.
  • Assessed cAMP-responsive element binding protein (CREB) activation.
  • Investigated Src kinase activation, receptor phosphorylation, and protein-receptor interactions (GRK2, beta-arrestin).
  • Analyzed MAPK pathway activation.

Main Results:

  • TARC impaired fenoterol's ability to activate CREB in T cells.
  • TARC induced Src kinase activation, leading to GRK2 and beta-arrestin translocation.
  • TARC promoted Src-dependent beta(2)-AR phosphorylation and association with GRK2/beta-arrestin.
  • Fenoterol enhanced Src and ERK phosphorylation upon TARC pretreatment, unlike CREB.

Conclusions:

  • TARC exposure impairs beta(2)-AR function in T cells via Src-dependent GRK2 activation.
  • This leads to receptor phosphorylation, beta-arrestin binding, and a signaling switch from cAMP to MAPK pathways.
  • Aberrant T cell control by TARC may promote T cell-mediated inflammation in asthma.